<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471471</url>
  </required_header>
  <id_info>
    <org_study_id>04-173</org_study_id>
    <secondary_id>NCI-2009-00159</secondary_id>
    <secondary_id>PCI-IRB-0607048</secondary_id>
    <secondary_id>CDR0000544402</secondary_id>
    <nct_id>NCT00471471</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery</brief_title>
  <official_title>Safety and Immunogenicity of Vaccination With Multi-Epitope Peptide Vaccine Containing MART-1, gp100, and Tyrosinase Peptides Given With the Combination of GMCSF and CpG Oligonucleotide (CpG 7909) in ISA-Oil Adjuvant for Patients With Recurrent Inoperable Stage III or Stage IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmad Tarhini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptides may help the body build an effective immune response&#xD;
      to kill tumor cells. Giving vaccine therapy together with GM-CSF, CpG 7909, and incomplete&#xD;
      Freund's adjuvant may make a stronger immune response and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the side effects and how well vaccine therapy works&#xD;
      in treating patients with recurrent stage III or stage IV melanoma that cannot be removed by&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of a peptide vaccine comprising MART-1:27-35 peptide, gp100:209-217&#xD;
           (210M) peptide, and tyrosinase peptide with sargramostim (GM-CSF) and CpG 7909&#xD;
           emulsified in incomplete Freund's adjuvant in patients with unresectable recurrent stage&#xD;
           III or IV melanoma.&#xD;
&#xD;
        -  Determine the efficacy of immunoadjuvants CpG 7909 and GM-CSF, in terms of a strong&#xD;
           antigen-specific CD8+ T-cell response, in these patients.&#xD;
&#xD;
        -  Determine the anti-pigmentary response to this regimen in these patients.&#xD;
&#xD;
        -  Determine the anti-tumor response, in terms of objective tumor regression,&#xD;
           progression-free survival, and overall survival, in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients receive peptide vaccine comprising MART-1:27-35 peptide, gp100:209-217 (210M)&#xD;
      peptide, and tyrosinase peptide with sargramostim (GM-CSF) and CpG 7909 emulsified in&#xD;
      incomplete Freund's adjuvant subcutaneously on days 1 and 15. Treatment repeats every 28 days&#xD;
      for up to 13 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are collected at baseline, day 50-53, and day 91-94. Samples are examined by&#xD;
      ELISPOT assay to measure lymphocyte immune response and by flow cytometry for biomarker&#xD;
      quantification and T-cell response.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically for at least 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Number of grade 2 or greater allergic reactions (including generalized urticaria) or any grade 3 or greater adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunologic response</measure>
    <time_frame>up to 94 days</time_frame>
    <description>Change in the circulating effector T-cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor regression</measure>
    <time_frame>2 months</time_frame>
    <description>Change in tumor size will be performed at the end of cycle 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depigmentation evaluation</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Change in cutaneous depigmentation using careful inspection of the skin of the torso by a Wood's lamp.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Intraocular Melanoma</condition>
  <condition>Malignant Conjunctival Neoplasm</condition>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Peptide Vaccine + GM-CSF + Pfizer 3512676 in-ISA Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The water-in-oil emulsion will consist of peptide (100 mcg/0.1 mL), GM-CSF (80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water), Pfizer PF3512676 (0.6 mg/0.04 mL using 15mg/mL vial) and 0.20 mLl of sterile saline.&#xD;
Vaccination will be given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peptide vaccine</intervention_name>
    <description>Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides</description>
    <arm_group_label>Peptide Vaccine + GM-CSF + Pfizer 3512676 in-ISA Oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).</description>
    <arm_group_label>Peptide Vaccine + GM-CSF + Pfizer 3512676 in-ISA Oil</arm_group_label>
    <other_name>Sargramostim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF3512676</intervention_name>
    <description>0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).</description>
    <arm_group_label>Peptide Vaccine + GM-CSF + Pfizer 3512676 in-ISA Oil</arm_group_label>
    <other_name>CpG 7909</other_name>
    <other_name>agatolimod</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed melanoma meeting the following criteria:&#xD;
&#xD;
               -  Unresectable recurrent disease&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
               -  Cutaneous, ocular, or mucosal melanoma&#xD;
&#xD;
          -  Measurable disease as defined by the RECIST criteria&#xD;
&#xD;
          -  HLA-A2 positive&#xD;
&#xD;
          -  Prior brain metastases allowed provided adequate surgical or radiologic treatment for&#xD;
             brain disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  WBC ≥ 3,000/mm³&#xD;
&#xD;
          -  Lymphocytes ≥ 1,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Lactic dehydrogenase ≤ 2.0 times ULN&#xD;
&#xD;
          -  aPTT &lt; 40 seconds&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for ≥ 1 week before, during, and for&#xD;
             ≥ 2 weeks after completion of study therapy&#xD;
&#xD;
          -  No conditions of immunosuppression&#xD;
&#xD;
          -  Negative titers for antinuclear antibody (≤ 1/80) and antidouble stranded DNA (≤ 1/10)&#xD;
&#xD;
          -  No serious illnesses including, but not limited to, any of the following:&#xD;
&#xD;
               -  Bleeding disorders&#xD;
&#xD;
               -  Autoimmune diseases&#xD;
&#xD;
               -  Severe obstructive or restrictive pulmonary diseases&#xD;
&#xD;
               -  Active systemic infections&#xD;
&#xD;
               -  Inflammatory bowel disorders&#xD;
&#xD;
          -  No serious cardiovascular disease including, but not limited to, any of the following:&#xD;
&#xD;
               -  Uncontrolled congestive heart failure&#xD;
&#xD;
               -  Hypertension&#xD;
&#xD;
               -  Cardiac ischemia&#xD;
&#xD;
               -  Myocardial infarction,&#xD;
&#xD;
               -  Severe cardiac arrhythmia&#xD;
&#xD;
          -  HIV1 and 2 negative&#xD;
&#xD;
          -  HTLV-1 negative&#xD;
&#xD;
          -  Hepatitis B and C negative&#xD;
&#xD;
          -  No significant psychiatric disease, medical intervention, or other condition that, in&#xD;
             the opinion of the principal investigator, would limit study compliance&#xD;
&#xD;
          -  No active infection within the past week, including unexplained fever (temperature &gt;&#xD;
             38.1°C)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Fully recovered from prior major surgery&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas),&#xD;
             hormonal therapy, radiotherapy, or biological therapy&#xD;
&#xD;
          -  More than 1 week since prior antibiotics&#xD;
&#xD;
          -  More than 28 days since prior investigational agent&#xD;
&#xD;
          -  No prior vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase&#xD;
             (368-376, 370D) peptides alone or in combination&#xD;
&#xD;
               -  Patients with history of vaccination with peptides other than MART-1 (26-35,&#xD;
                  27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) peptides allowed&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent systemic immunosuppressive therapy,&#xD;
             including steroids&#xD;
&#xD;
               -  Patients on maintenance steroids given at physiologic doses because of adrenal&#xD;
                  insufficiency are eligible&#xD;
&#xD;
          -  More than 2 weeks since prior and no concurrent treatment with systemic steroids,&#xD;
             including oral steroids, continuous use of topical steroid creams or ointments, or any&#xD;
             inhaled steroids&#xD;
&#xD;
          -  No concurrent anticoagulants, except to keep an indwelling line patent&#xD;
&#xD;
          -  No other concurrent anticancer therapy, including chemotherapy, immunotherapy,&#xD;
             radiotherapy, experimental programs, and/or surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad A. Tarhini, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tarhini AA, Leng S, Moschos SJ, Yin Y, Sander C, Lin Y, Gooding WE, Kirkwood JM. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother. 2012 May;35(4):359-66. doi: 10.1097/CJI.0b013e31825481fe. Erratum in: J Immunother. 2012 Oct;35(8):650.</citation>
    <PMID>22495394</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>May 8, 2007</study_first_submitted>
  <study_first_submitted_qc>May 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2007</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Ahmad Tarhini</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <keyword>metastatic intraocular melanoma</keyword>
  <keyword>conjunctival melanoma</keyword>
  <keyword>stage IIIA melanoma</keyword>
  <keyword>stage IIIB melanoma</keyword>
  <keyword>stage IIIC melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Conjunctival Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

